These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1067 related articles for article (PubMed ID: 23549180)

  • 1. Commentary: how to report instrumental variable analyses (suggestions welcome).
    Swanson SA; Hernán MA
    Epidemiology; 2013 May; 24(3):370-4. PubMed ID: 23549180
    [No Abstract]   [Full Text] [Related]  

  • 2. Reporting instrumental variable analyses.
    Boef AG; Dekkers OM; le Cessie S; Vandenbroucke JP
    Epidemiology; 2013 Nov; 24(6):937-8. PubMed ID: 24076999
    [No Abstract]   [Full Text] [Related]  

  • 3. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis.
    Davies NM; Smith GD; Windmeijer F; Martin RM
    Epidemiology; 2013 May; 24(3):352-62. PubMed ID: 23532054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues in the reporting and conduct of instrumental variable studies: a systematic review.
    Davies NM; Smith GD; Windmeijer F; Martin RM
    Epidemiology; 2013 May; 24(3):363-9. PubMed ID: 23532055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative falsification of instrumental variables assumption using balance measures.
    Ali MS; Uddin MJ; Groenwold RH; Pestman WR; Belitser SV; Hoes AW; de Boer A; Roes KC; Klungel OH
    Epidemiology; 2014 Sep; 25(5):770-2. PubMed ID: 25076152
    [No Abstract]   [Full Text] [Related]  

  • 6. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs.
    Warner TD; Mitchell JA
    Lancet; 2008 Jan; 371(9608):270-3. PubMed ID: 18207021
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to invited commentary. Rose et al. respond to "G-computation and standardization in epidemiology".
    Rose S; Snowden JM; Mortimer KM
    Am J Epidemiol; 2011 Apr; 173(7):743-4. PubMed ID: 21415030
    [No Abstract]   [Full Text] [Related]  

  • 8. Do case control studies on coxibs tell us anything new?
    Brune K
    Rheumatology (Oxford); 2007 May; 46(5):730. PubMed ID: 17309891
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
    Singh H
    South Med J; 2007 Aug; 100(8):856. PubMed ID: 17713322
    [No Abstract]   [Full Text] [Related]  

  • 10. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes.
    Rassen JA; Schneeweiss S; Glynn RJ; Mittleman MA; Brookhart MA
    Am J Epidemiol; 2009 Feb; 169(3):273-84. PubMed ID: 19033525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting to the heart of the matter: a trialist's approach to the use of nonsteroidal anti‑inflammatory drugs for patients with chronic pain syndromes.
    Farkouh ME
    Pol Arch Med Wewn; 2013; 123(9):433-5. PubMed ID: 24084249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable selection for propensity score estimation via balancing covariates.
    Zhu Y; Schonbach M; Coffman DL; Williams JS
    Epidemiology; 2015 Mar; 26(2):e14-5. PubMed ID: 25643109
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary: regression discontinuity design: let's give it a try to evaluate medical and public health interventions.
    Vandenbroucke JP; le Cessie S
    Epidemiology; 2014 Sep; 25(5):738-41. PubMed ID: 25076150
    [No Abstract]   [Full Text] [Related]  

  • 15. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 16. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How statistics can be used to promote better health care.
    Sinclair J
    Nurs Times; 1999 Jun 23-29; 95(25):44-6. PubMed ID: 10497591
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences between marginal structural models and conventional models in their exposure effect estimates: a systematic review.
    Suarez D; Borràs R; Basagaña X
    Epidemiology; 2011 Jul; 22(4):586-8. PubMed ID: 21540744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM; Lévesque LE; Zhang B
    Heart; 2007 Feb; 93(2):189-94. PubMed ID: 16849374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.